|Dr. Adam Mark Hill Ph.D.||CEO & Director||385k||N/A||1980|
|Mr. Matthew Hall||Chief Financial Officer||N/A||N/A||N/A|
|Prof. Tariq Sethi M.D., B.Sc., M.A., Ph.D., FRCP||Chief Scientific Officer||N/A||N/A||N/A|
|Ms. ClÃ©a Rosenfeld||Head of Investor Relations||N/A||N/A||N/A|
|Mr. Ron Kirschner||Gen. Counsel & Company Sec.||N/A||N/A||N/A|
|Dr. James R. Jett M.D.||Chief Medical Officer of US||N/A||N/A||N/A|
|Mr. Maarten Brusse||Chief Commercial Officer of Asia||N/A||N/A||N/A|
|Mr. Shane Smith||Sr. VP of Market Access & Reimbursement Oncimmune (Usa)||N/A||N/A||N/A|
|Mr. Cameron Barnard||Chief Bus. Officer||N/A||N/A||N/A|
|Mr. Andrew Millet BA, FCA, MBA||Exec.||N/A||N/A||1967|
Oncimmune Holdings plc develops and commercializes technologies that enable cancer diagnosis in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, a blood test for early detection of lung cancer. The company also develops SeroTag, a platform that is used to discover and validate biomarkers that can help stratify patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID disease-specific stratification panels. Oncimmune Holdings plc was incorporated in 2015 and is based in Nottingham, the United Kingdom.
Oncimmune Holdings plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.